Robotic Surgery Offers Precision and Safety in Pediatric Adrenal Tumor Removal
In a field where millimeters can mean the difference between lifelong hormone dependency and full physiological recovery, robotic-assisted surgery is redefining what’s possible in pediatric urology. A recent case report from Shanghai Children’s Hospital, affiliated with Shanghai Jiao Tong University, demonstrates how advanced robotic platforms can safely and effectively treat rare adrenal tumors in children—offering a compelling alternative to traditional open or laparoscopic approaches.
The case, published in the Journal of Clinical Pediatric Surgery, details the successful use of robot-assisted laparoscopic partial adrenalectomy (RALPA) in an 8-year-old boy diagnosed with pheochromocytoma—a rare neuroendocrine tumor arising from the adrenal medulla. The procedure not only preserved healthy adrenal tissue but also minimized intraoperative complications, shortened hospital stay, and ensured rapid functional recovery. This achievement underscores a broader shift in pediatric surgical oncology: the integration of high-precision robotics into complex endocrine procedures once deemed too delicate for minimally invasive techniques.
Pheochromocytomas, though uncommon in children—with an estimated incidence of just 2 per million—pose significant clinical challenges due to their catecholamine-secreting nature. These tumors can trigger life-threatening hypertensive crises, arrhythmias, and metabolic instability, especially during surgical manipulation. Historically, open adrenalectomy was the standard, but advances in laparoscopy have enabled less invasive options. However, in pediatric patients, the anatomical constraints of a smaller abdominal cavity, coupled with the need for extreme precision to avoid tumor rupture or excessive hormone release, have limited the applicability of conventional laparoscopy.
Enter robotic surgery. Equipped with 3D high-definition visualization, wristed instruments that mimic human hand movements with seven degrees of freedom, and motion-scaling technology that filters out tremors, robotic systems like the da Vinci platform offer unparalleled control in confined spaces. For adrenal surgery—particularly partial resections where preservation of functional cortex is critical—these advantages translate into tangible clinical benefits.
In the Shanghai case, the patient presented with severe hypertension (peaking at 200/140 mmHg), headaches, vomiting, and diaphoresis. Imaging revealed a 4.3 cm × 3.9 cm well-circumscribed mass in the right adrenal gland, with biochemical confirmation via elevated 24-hour urinary vanillylmandelic acid (VMA) and plasma metanephrines. After two weeks of preoperative preparation—including alpha-blockade with phenoxybenzamine and aggressive volume expansion to mitigate the risk of post-resection hypotension—the surgical team proceeded with RALPA.
The operation lasted 105 minutes within the abdominal cavity. Surgeons meticulously dissected the tumor, which exhibited engorged surface vasculature, while preserving a rim of normal adrenal tissue located superior to the lesion. A brief intraoperative hemorrhage from a previously sealed feeding artery was swiftly controlled using an additional trocar and Hem-o-lock clips—a maneuver facilitated by the robot’s stable platform and precise instrument control. Total blood loss was 400 mL, requiring transfusion, but hemodynamic stability was maintained throughout thanks to close coordination between the surgical and anesthesia teams.
Critically, the decision to perform a partial rather than total adrenalectomy was strategic. In children—especially those with genetic syndromes like von Hippip-Lindau (VHL), which predisposes to bilateral tumors—preserving even a small portion of healthy adrenal cortex can prevent lifelong glucocorticoid and mineralocorticoid replacement. The Shanghai team’s ability to identify and spare normal tissue adjacent to the tumor highlights the precision enabled by robotic magnification and dexterity.
Postoperatively, the child recovered swiftly. Blood pressure normalized within days, catecholamine metabolites returned to baseline, and he was discharged on postoperative day six. At six-month follow-up, imaging showed no recurrence, and endocrine function remained intact—no small feat in pediatric adrenal surgery.
This case is not an isolated breakthrough. A literature review accompanying the report identified only six prior pediatric cases of robot-assisted adrenalectomy for pheochromocytoma worldwide as of March 2021—most involving VHL syndrome and bilateral disease. Notably, the earliest reported pediatric RALPA dates back to 2006, yet adoption has remained limited, particularly in non-syndromic or sporadic cases like the one in Shanghai. The current report thus expands the evidence base for robotic surgery in non-VHL pediatric pheochromocytoma, suggesting its utility extends beyond genetically predisposed populations.
What sets this case apart is not just the technical success, but the deliberate emphasis on functional preservation in a young patient with no family history or known syndrome. It challenges the notion that partial adrenalectomy is only justified in bilateral or recurrent disease. Instead, it advocates for a more nuanced, tissue-sparing philosophy—even in unilateral tumors—given the lifelong implications of adrenal insufficiency in children.
From a surgical standpoint, robotic assistance mitigates several key limitations of traditional laparoscopy. The two-dimensional view, rigid instruments, and fulcrum effect inherent in standard laparoscopy can hinder fine dissection near critical vascular structures—especially problematic in highly vascular tumors like pheochromocytomas. In contrast, the robotic system’s immersive 3D optics and articulated tools allow for delicate, tremor-free movements along tissue planes, reducing the risk of inadvertent tumor compression and catecholamine surges.
Moreover, in heavier pediatric patients—this child had a BMI ≥24 kg/m², classified as overweight—excess intra-abdominal fat can obscure anatomy and increase bleeding risk during dissection. The robotic platform’s superior ergonomics and bipolar energy control proved advantageous in managing fatty tissue and achieving hemostasis, a point emphasized by the authors.
The broader implications extend beyond technique. As healthcare systems increasingly prioritize value-based care, metrics such as length of stay, transfusion requirements, and readmission rates gain importance. In this case, a six-day hospitalization compares favorably with historical open series, where stays often exceeded 7–10 days. While robotic surgery carries higher upfront costs, potential reductions in complications, faster recovery, and avoidance of lifelong hormone therapy may offset these expenses over time—particularly in pediatric populations with decades of life ahead.
Nevertheless, the authors acknowledge limitations. With only seven pediatric RALPA cases reported globally—including their own—large-scale comparative data are lacking. Randomized trials are impractical given the rarity of the condition, but multi-institutional registries could help clarify long-term outcomes, recurrence rates, and endocrine function preservation. Until then, decisions must be guided by surgical expertise, institutional experience, and individualized patient factors.
The Shanghai Children’s Hospital team, led by Xie Hua, has been at the forefront of pediatric robotic urology in China. Their prior work, including a 2019 study on robot-assisted adrenalectomy in children, laid the groundwork for this refined application in hormone-active tumors. Their protocol—emphasizing preoperative optimization, intraoperative hemodynamic vigilance, and cortical-sparing intent—offers a replicable model for centers adopting this technology.
Looking ahead, the integration of robotics into pediatric endocrine surgery is likely to grow, driven by technological refinements, surgeon training, and accumulating evidence. Next-generation platforms with smaller instruments, improved haptic feedback, and AI-assisted navigation may further enhance safety and accessibility. For now, however, the message is clear: in the hands of experienced teams, robotic surgery can deliver precision, safety, and functional preservation in some of the most challenging pediatric tumor cases.
This case also reflects a paradigm shift in surgical oncology—from radical resection to organ- and function-preserving strategies. In an era where survivorship and quality of life are as important as cure, minimizing long-term morbidity is paramount. For an 8-year-old boy facing a lifetime of potential hormone dependence, the ability to retain even a sliver of healthy adrenal tissue isn’t just a surgical triumph—it’s a gift of physiological autonomy.
As robotic platforms become more widespread in pediatric centers worldwide, cases like this will serve as benchmarks for what’s achievable. They remind us that innovation in surgery isn’t just about adopting new tools, but about reimagining what’s possible for the youngest and most vulnerable patients.
Chen Yan, Zhou Lijun, Wang Yaping, Xie Hua. Department of Urology, Shanghai Children’s Hospital, Shanghai Jiao Tong University, Shanghai 200062, China. Journal of Clinical Pediatric Surgery, 2021, 20(8): 731–736. DOI: 10.12260/lcxewkzz.2021.08.006.